Sareum Holdings to showcase potential of new cancer drug at leading industry conference
The poster presentation is based on pre-clinical work on its TYK2/JAK1 inhibitor, SAR-20351
Company
Sareum Holdings PLC
LON:SAR
Sareum Holdings (AIM:SAR) is a clinical-stage biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer. The Company is focused on developing next generation small molecules which modify the activity of the JAK kinase family and have best-in-class potential. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential treatment for a range of autoimmune diseases, including psoriasis, and has completed Phase 1 clinical development.
239 stories · page 3 of 12
Sareum confident partner will find funding solution for promising cancer drug
SRA737 could be worth up to US$88mln in future milestone payments and royalties, the company confirmed
Archive
Proactive news snapshot: Union Jack Oil, Oncimmune, Ariana Resources …
A glance at some of the day's highlights from the Proactive Investors newswire
Investments and investor services
Angus Energy considers sale of Brockham licences after disappointing drilling programme
A look at the day's major movers, including Rose Petroleum, Craneware, CVS, Adept4, Merlin, Mirriad and Costain
Investments and investor services
FTSE 100 closes higher on day and week as world leaders meet
The mid-cap FTSE 250 added over 147 points to close at 19,462 on Friday
Sareum notes decision by Sierra Oncology to explore options for future development of SRA737
SRA737 is a checkpoint kinase 1 that Sierra licensed from Sareum back in 2016
Archive
Proactive news snapshot: 88 Energy, Tekcapital, AFC Energy, SDX Energy …
A glance at some of the day's highlights from the Proactive Investors newswire
Kibo Energy the day's top riser as its moves to secure total ownership of the Bordersley project
A look at the day's major movers, including 88 Energy, Two Shields, Inland Homes, Avingtrans, Creightons, RM2 and RPS Group
Sareum raises £680k as it looks to take its TYK2/JAK1 inhibitors into the clinic next year
Sareum raised the money by selling 170.37mln new shares at 0.4p each – a 25% discount to Tuesday’s closing price
Archive
FTSE 100 still stuck in neutral; G20 meeting can't come soon enough
Bitcoin is up more than 10% but the shine has come off gold a bit
Investments and investor services
Maistro shares to become just a blurred memory
A look at the day's major movers, including Great Western Mining, Majestic Wine, Ascent, Ferguson and Just Group
Archive
Proactive news snapshot: Tekcapital, Quadrise Fuels International, Sareum Holdings …
A glance at some of the day's highlights from the Proactive Investors newswire
Sareum surges as it signals progress on pre-clinical programmes
"The potential for our two preclinical TYK2/JAK1 inhibitors in autoimmune diseases and cancer is gaining increasing clinical validation and we are convinced that SDC-1801 and SDC-1802 represent strong and well-differentiated candidates to a
Archive
Proactive news snapshot: Argo Blockchain, Sareum Holdings, WideCells Group …
A glance at some of the day's highlights from the Proactive Investors newswire
Investments and investor services
EQTEC gives ground as it draws on its loan facility
A look at the day's major movers, including Carclo, Sareum, Karelian, Kier, Fulcrum, Microsaic, Dignity and Scapa
Sareum Holdings hails early-stage efficacy data for cancer drug
The latest update was provided at a America's largest and most prestigious cancer conference
Investments and investor services
FTSE 100 closes higher despite continued trade worries
The UK's blue-chip benchmark added over 23 points to close at 7,184
Immuno-oncology: All you wanted to know but were too afraid to ask
Essentially, immuno-oncology involves developing drugs that use the body’s own immune system to fight cancers
Gaming Realms surges after striking deal with SG Digital
A look at the day's major movers, including RA International, Genus, LiDCO, Just Group, Yu Group and Thomas Cook